

Research



Cite this article: Mikonranta L, Buckling A, Jalasvuori M, Raymond B. 2019 Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host. *Biol. Lett.* **15**: 20180895.

<http://dx.doi.org/10.1098/rsbl.2018.0895>

Received: 21 December 2018

Accepted: 10 February 2019

Subject Areas:

health and disease and epidemiology, evolution

Keywords:

antibiotic resistance, bacteriophage, *Enterobacter cloacae*, gut infection, insect model, phage therapy

Author for correspondence:

Lauri Mikonranta

e-mail: lauri.mikonranta@york.ac.uk

Evolutionary biology

Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host

Lauri Mikonranta^{1,2}, Angus Buckling¹, Matti Jalasvuori³ and Ben Raymond¹

¹School of Biosciences, University of Exeter, Penryn Campus, Penryn, Cornwall TR10 9FE, UK

²Department of Biology, University of York, Wentworth Way, York YO10 5DD, UK

³Department of Biological and Environmental Science, Nanoscience Center, University of Jyväskylä, PL 35, 40014 Jyväskylä, Finland

LM, 0000-0003-4842-1448; BR, 0000-0002-3730-0985

Phage therapy is attracting growing interest among clinicians as antibiotic resistance continues becoming harder to control. However, clinical trials and animal model studies on bacteriophage treatment are still scarce and results on the efficacy vary. Recent research suggests that using traditional antimicrobials in concert with phage could have desirable synergistic effects that hinder the evolution of resistance. Here, we present a novel insect gut model to study phage–antibiotic interaction in a system where antibiotic resistance initially exists in very low frequency and phage specifically targets the resistance bearing cells. We demonstrate that while phage therapy could not reduce the frequency of target bacteria in the population during positive selection by antibiotics, it alleviated the antibiotic induced blooming by lowering the overall load of resistant cells. The highly structured gut environment had pharmacokinetic effects on both phage and antibiotic dynamics compared with *in vitro*: antibiotics did not reduce the overall amount of bacteria, demonstrating a simple turnover of gut microbiota from non-resistant to resistant population with little cost. The results imply moderate potential for using phage as an aid to target antibiotic resistant gut infections, and question the usefulness of *in vitro* inferences.

1. Introduction

Problems arising from antibiotic resistant infections are set to increase worldwide. As a consequence, bacteriophages (bacteria-specific viruses) have started to attract serious consideration as antimicrobial agents after this approach was largely forgotten for decades in the Western world [1,2]. However, their efficacy as therapeutic agents remains controversial [3]. Some of the *in vivo* work promises therapeutic potential in insect [4], mouse [5] and human infections [6], and *in vitro* experiments show overwhelming evidence of phages controlling bacterial population sizes without adverse effects on non-target bacteria [7]. Despite this, the few existing modern and properly controlled medical trials report varying success [3,6,8]. Key limitations of phage therapy include high specificity, ease at which bacteria can evolve resistance, and localized activity in the body.

It has been argued that phages may be of particular therapeutic value when combined with antibiotics, by constraining the emergence and spread of antibiotic resistance [9]. A good example of recent success in combination treatment comes from a difficult chronic *Pseudomonas aeruginosa* infection in human aortic graft [10]. Theoretically, phages may limit antibiotic resistance during treatment because of reduction in population size and synergistic costs of resistance [9]. Moreover, with cases where antibiotic resistance is

carried on plasmids, phage can be used to directly target the plasmid carrying cells [11]. However, this latter approach has only been investigated *in vitro* [11,12], which ignores a plethora of selection pressures towards both the host bacteria and the phage, such as host immune system, spatial structures within the tissues, nutrient availability, and presence of native microbial microbiota [13].

Here, we studied the effects of antibiotic and phage treatment on bacterial load and frequency of resistance in a gnotobiotic insect gut model system, where phage target the bacteria harbouring antibiotic resistance plasmids. We compare these findings with an *in vitro* context to assess the usefulness of inferring *in vivo* dynamics from *in vitro* studies. A full factorial set-up of antibiotics and phage was orally administered to cabbage looper (*Trichoplusia ni*) larvae harbouring *Enterobacter cloacae* gut bacteria and a low initial frequency of antibiotic resistance plasmid. We show that targeting the tetracycline resistant cells with phage could not prevent the increase in resistance frequency in the presence of antibiotics. However, phage reduced the bacterial population size when plasmid was driven to high frequency with antibiotic selection.

2. Material and methods

Although it has been argued that lepidopterans lack a resident microbiome [14], *Enterobacter cloacae* forms a persistent gut association with lepidopteran larvae [15] after oral inoculation. The strain used was isolated from *Plutella xylostella* in the insectary of the University of Oxford. Two spontaneous antibiotic resistant mutants, ANC C2 (*rif^R*) and 11.1B (*strep^R* + *nal^R*) were used in this experiment. The IncP-type plasmid RP4, coding for tetracycline resistance, is usually conjugative [16], and the lytic, plasmid dependent tectiviruses PRD1 specifically infects RP4 bearing cells by recognizing the bacterial sex-apparatus [17]. However, in this system the plasmid is essentially non-conjugative and functions as a carrier of tetracycline resistance and phage receptor genes. The mechanistic basis for low RP4 conjugation in these *E. cloacae* strains is unclear. Given that the phage remains infective, it could be that ANC C2 rifampicin resistant mutant was an important recipient for the plasmid rather than that 11.1B(RP4) lacked the ability to express pili. Although rifampicin resistance mutations are most often polymerase related, known mechanisms in *Enterobacteriaceae* include elongated or abundant outer membrane lipopolysaccharide chains [18] that could theoretically interfere with conjugation (but, see: [19]).

The *in vitro* experiment used 200 μ l cultures on a 96-well plate with Luria-Bertani medium (LB) and 0.1% starting frequency of plasmid. Twenty-four replicate populations were subjected to full factorial antibiotic (AB) and phage (P) treatment: AB- P-, AB- P+, AB+ P-, and AB+ P+, respectively. The antibiotic treatments were set to 12 μ g ml⁻¹ tetracycline and phage starting density to 5×10^7 phage particles. The growth in optical density (600 nm) at 30°C was recorded at 24 h with a spectrophotometer. Plasmid frequency and transconjugants were sampled from a subset ($N = 44$) of populations at 24 h by selective plating.

The *T. ni* were maintained as follows. The adults, fed with 100 mM sucrose solution, were allowed to mate and lay eggs on paper strips in flight chambers. The eggs were placed in autoclaved, single-filter vented, 305 \times 203 \times 100 mm Genesis™ containers for surgical instruments to maintain sterile conditions while allowing gas exchange. Hatched larvae were allowed to feed on Hoffman diet (288 g wheatgerm, 132 g casein, 117 g sucrose, 70 g agar, 57 g dried brewers yeast, 37.5 g Wesson's salts, 6 g sorbic acid, 3.75 g cholesterol, 3.75 g methyl-4-hydroxybenzoate and 2 g Vanderzant vitamin mixture in 2750 ml water)

[20]. The liquid medium was poured into a sterile steel mould and solidified to diet cubes with approximately 25 mm edges. The cubes were placed on Petri dish covers inside the containers. All rearing and *in vivo* bacterial work was carried out at 25°C. For population maintenance, 50–60 pupae were removed from their cocoons per flight chamber and allowed to emerge and mate to start a new generation of hosts.

For inoculating the larval gut with *E. cloacae*, clones ANC C2 and 11.1B bearing RP4 were grown overnight in LB (30°C, 180 r.p.m. shaking), the 11.1B diluted 1:10 with 0.85% NaCl, and then mixed together in a 50:1 ratio. The frequency of the plasmid bearing cells was counted by dilution plating as 0.072% and bacterial density approximately 1.2×10^8 colony-forming units (CFU). Diet cubes were dipped in this solution, dried for 5 min, and 3rd instar larvae were allowed to feed on this bacterial diet for 30 h. The larvae were then subjected to the AB- P-, AB- P+, AB+ P-, and AB+ P+ treatments. Tetracycline (200 μ g ml⁻¹ final concentration) was added directly to the autoclaved diet mix and 30 μ l of 10^{10} plaque-forming units (PFU) ml⁻¹ filtered phage lysate was pipetted onto each face of the phage treatment diet cubes. The experiment was carried out in two independent batches (final $N = 156$ larvae). After 96 h, the larvae were surface sterilized with 70% alcohol and homogenized in 500 μ l 0.85% NaCl with Qiagen Tissuelyser II™. The homogenate was serially diluted and plated on 12 μ g ml⁻¹ tetracycline, 12 μ g ml⁻¹ tetracycline + 100 μ g ml⁻¹ rifampicin, and LB plates to calculate the frequencies of plasmid carriers and transconjugants, and total density of bacteria. Twenty-four bacterial clones from the phage treatment serial dilutions on tetracycline were tested for resistance against the ancestral phage with a phage plaque overlay assay. Phage survival in the gut was confirmed by overlaying homogenized larval faecal samples on ancestral 11.1B(RP4) lawn on soft agar and observing plaque formation ($N = 24$).

Treatment effects on densities and frequencies in both experiments were analysed with SPSS Statistics 21.0 with antibiotics, phage, and antibiotics * phage interaction in an ANOVA-GLM model. *Post hoc* multiple comparisons were Bonferroni corrected.

3. Results

In vitro, antibiotics and phage had synergistic effects on the total density of bacteria at 24 h (AB: $F_{1,96} = 3528.0$, $p < 0.001$; P: $F_{1,96} = 73.7$, $p < 0.001$; AB * P: $F_{1,96} = 97.0$, $p < 0.001$). Multiple comparisons showed that there was no phage effect in absence of antibiotics, but other pairwise differences were highly significant ($p < 0.001$, figure 1a). Thus, single treatment allowed compensatory growth of the non-target strain, but this effect was reduced for the plasmid carriers in the presence of antibiotics. The plasmid went to near fixation in the presence of antibiotics ($F_{1,44} = 8864.4$, $p < 0.001$) regardless of the phage (P and AB * P: $p > 0.05$). This was contrary to previous studies with the same plasmid and phage in *E. coli* [12]. The increase in frequency was not the result of conjugational transfer, because unlike in *E. coli*, RP4 had very low conjugation rate in *E. cloacae*: transconjugants were present in only one of the 44 sampled *in vitro* populations (AB+ P- treatment at a very low frequency). We also confirmed that the phage remained infective even with low conjugation. The cost of plasmid carriage in the absence of antibiotics manifested itself as complete plasmid extinction (at least below the detection threshold of 67 c.f.u. ml⁻¹) in all sampled populations (figure 1b). This was the case even though RP4 has been reported to be of low cost and rapidly evolve towards no cost through chromosomal compensatory mutations [21].




Figure 1. Dynamics *in vitro*. The density of bacteria (a), and the frequency of plasmid bearing cells (b) in liquid culture after 24 h factorial antibiotic (AB) and phage (P) treatments. Error bars are ± 1 s.e.; ** denotes $p < 0.001$ difference.

In vivo patterns of plasmid dynamics were mainly similar to that observed *in vitro*, but the effects smaller. The non-targeted strain could fully compensate for the reduction in density of the competing strain (AB: $F_{1,156} = 0.1$, $p = 0.77$), and phage had no main effect on total bacterial load (P: $F_{1,156} = 3.0$, $p = 0.085$). Phage, however, lowered bacterial density in the presence of antibiotics (interaction: $F_{1,156} = 6.7$, $p = 0.011$), demonstrating that the treatment synergism was maintained *in vivo* (*post hoc* AB+ P- and AB+ P+, $p = 0.020$, figure 2a). Phage-susceptibility screening of evolved clones showed no emergence of resistance. Plasmid increased in frequency in all treatments, but tetracycline selection drove the majority of the population to be plasmid carriers with no effects of phage addition (effects on plasmid frequency, AB: $F_{1,156} = 845.0$, $p < 0.001$; P: $F_{1,156} = 0.6$, $p = 0.43$; AB * P: $F_{1,156} = 0.4$, $p = 0.55$ (figure 2b)). Thus, phage therapy could not restrict the spread of antibiotic resistance in the *T. ni* gut.

4. Discussion

Here, we investigated the effect of plasmid-targeting phage on the spread of antibiotic resistance plasmid *in vitro* and in an insect gut model. Different selective environment in the gut made treatment effects less pronounced compared with the liquid culture: for example, the increased complexity in spatial structures may have protected the plasmid from extinction in the absence of antibiotics, and thus allowed more non-resistant bacteria to coexist in the presence of tetracycline. This happened even though the antibiotic concentration in the diet was over 16 times higher than in the liquid culture and the experiment length four times

longer, allowing more time for potential fixation and/or extinction to happen. Phage driven reduction in the bacterial population size in the presence of tetracycline was also more moderate *in vivo*, but it is also notable that no detectable phage resistance emerged in the sampled populations. Surprisingly, antibiotics did not reduce the overall bacterial density in the gut, but rather replaced non-resistant cells with resistant ones while population size remained the same. In other words, antibiotics increased the relative fitness of the resistant strain without reducing the absolute fitness [22]. This was in contrast with liquid culture, where the plasmid went even closer to fixation in the presence of antibiotics, but resulted in lower total bacterial density, which suggests a greater growth cost associated with antibiotic resistance *in vitro*. We cannot attribute the inversion of fitness effects between *in vivo* and *in vitro* conditions (increase in plasmid frequency *in vivo*, and extinction *in vitro* in absence of antibiotics) directly to the plasmid, because it could also be due to unknown differences in the mutant strains. The result still highlights the limitations of making inferences from test tube dynamics.

In the absence of antibiotics neither *in vitro* nor *in vivo* regimes showed a phage effect on the bacterial population size, which was not surprising because of very low initial frequency of phage-susceptible (i.e. plasmid bearing) cells. Most importantly, when antibiotic selection increased the frequency of phage-susceptible cells by spreading antibiotic resistance, phage decreased the total density of bacteria. This effect was bigger *in vitro*, but also clearly visible in the insect gut. The gut lumen is a favourable environment for bacterial biofilm formation [23], which can offer non-resistant




Figure 2. Dynamics *in vivo*. The overall density of bacteria (a) and the frequency of plasmid bearing cells (b) in the larval guts after 96 h factorial antibiotic (AB) and phage (P) treatments. Error bars are ± 1 s.e.; * and ** denote $p < 0.05$ and $p < 0.001$ differences, respectively.

cells spatial protection from antibiotics [24] and/or from phage [25]. On the other hand, it could be that the observed phage efficacy to reduce bacterial load *in vivo* is partly due to their known ability to eradicate biofilms [26,27], which can be important for bacterial persistence in the insect gut [23].

One potential epidemiological implication of viable phage in the faeces is that the viral therapeutic agent could restrict ongoing pathogen transmission or be transmitted with the target pathogen [28]. The model system presented in this study allows the manipulation of structure and connectivity of the population of the treated organism and would be an interesting future endeavour towards epidemiological effects of phage therapy. Our findings have implications for therapeutic use of phage, especially considering synergistic evolutionary effects with antibiotics [9]. However, antibiotics overwhelmed the selection imposed by the phage, meaning that the relative effect remained rather small. This could be improved with using more efficient phage or phage cocktails in a way that can target wider niche space *in vivo* by, for example, biofilm specificity [27]. It has also been shown that the effect of phage on

plasmid maintenance can depend on the type of antibiotics that are used [29]. To conclude, within-organism pharmacokinetics and the spatial, temporal, and resource-related dynamics are very different from those in a test tube, having major effects on cost of resistance, magnitude of selection, and treatment efficacy even in a highly simplified and low diversity model system.

Data accessibility. Data are available from the Dryad Digital Repository at: <http://dx.doi.org/10.5061/dryad.sc54383> [30].

Authors' contributions. All authors conceived the study and designed the experiments. L.M. did the experimental work and analysed the data. All authors contributed to writing, approved the final version of the manuscript, and agree to be held accountable for the work performed.

Competing interests. No competing interests.

Funding. The work was funded by an MRC innovation award (MR/N013824/1), Academy of Finland grants (252411 and 297049) and Emil Aaltonen Foundation grant.

Acknowledgements. The authors thank Alex Robinson for assistance with *T. ni* rearing.

References

- Reardon S. 2014 Phage therapy gets revitalized: the rise of antibiotic resistance rekindles interest in a century-old virus treatment. *Nature* **510**, 15–17. (doi:10.1038/510015a)
- Alavidze Z *et al.* 2016 Silk route to the acceptance and re-implementation of bacteriophage therapy. *Biotechnol. J.* **11**, 595–600. (doi:10.1002/biot.201600023)
- Brussow H. 2017 Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality? *Expert Rev. Gastroenterol. Hepatol.* **11**, 785–788. (doi:10.1080/17474124.2017.1342534)
- Seed KD, Dennis JJ. 2009 Experimental bacteriophage therapy increases survival of *Galleria mellonella* larvae infected with clinically relevant strains of the *Burkholderia cepacia* complex. *Antimicrob. Agents Chemother.* **53**, 2205–2208. (doi:10.1128/AAC.01166-08)

5. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L. 2017 Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. *Cell Host Microbe* **22**, 38–47. (doi:10.1016/j.chom.2017.06.018)
6. Wright A, Hawkins C, Änggård E, Harper D. 2009 A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin. Otolaryngol.* **34**, 349–357. (doi:10.1111/j.1749-4486.2009.01973.x)
7. Abedon S. 2008 Phages, ecology, evolution. In *Bacteriophage ecology: population growth, evolution, and impact of bacterial viruses* (ed. S Abedon), pp. 1–28. Cambridge, UK: Cambridge University Press.
8. Sarker SA *et al.* 2016 Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. *EBioMedicine* **4**, 124–137. (doi:10.1016/j.ebiom.2015.12.023)
9. Torres-Barcelo C, Hochberg ME. 2016 Evolutionary rationale for phages as complements of antibiotics. *Trends Microbiol.* **24**, 249–256. (doi:10.1016/j.tim.2015.12.011)
10. Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. 2018 Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. *Evol. Med. Public Health* **2018**, 60–66. (doi:10.1093/emph/eoy005)
11. Jalasvuori M, Friman VP, Nieminen A, Bamford JK, Buckling A. 2011 Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. *Biol. Lett.* **7**, 902–905. (doi:10.1098/rsbl.2011.0384)
12. Ojala V, Laitalainen J, Jalasvuori M. 2013 Fight evolution with evolution: plasmid-dependent phages with a wide host range prevent the spread of antibiotic resistance. *Evol. Appl.* **6**, 925–932. (doi:10.1111/eva.12076)
13. Payne RJH, Jansen VA. 2000 Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. *Clin. Pharmacol. Ther.* **68**, 225–230. (doi:10.1067/mcp.2000.109520)
14. Hammer TJ, Janzen DH, Hallwachs W, Jaffe SP, Fierer N. 2017 Caterpillars lack a resident gut microbiome. *Proc. Natl Acad. Sci. USA* **114**, 9641–9646. (doi:10.1073/pnas.1707186114)
15. Watanabe K, Abe K, Sato M. 2000 Biological control of an insect pest by gut-colonizing *Enterobacter cloacae* transformed with ice nucleation gene. *J. Appl. Microbiol.* **88**, 90–97. (doi:10.1046/j.1365-2672.2000.00904.x)
16. Datta N, Hedges RW, Shaw EJ, Sykes RB, Richmond MH. 1971 Properties of an R factor from *Pseudomonas aeruginosa*. *J. Bacteriol.* **108**, 1244–1249.
17. Olsen RH, Siak J-S, Grey RH. 1974 Characteristics of PRD1, a plasmid-dependent broad host range DNA bacteriophage. *J. Virol.* **14**, 689–699.
18. Goldstein BP. 2014 Resistance to rifampicin: a review. *J. Antibiot.* **67**, 625–630. (doi:10.1038/ja.2014.107)
19. Pérez-Mendoza D, de la Cruz F. 2009 *Escherichia coli* genes affecting recipient ability in plasmid conjugation: are there any? *BMC Genomics* **10**, 71. (doi:10.1186/1471-2164-10-71)
20. Knipling E, Smith C. 1966 Semisynthetic diet used to rear *Heliothis* and *Trichoplusia*. In *Insect colonisation and mass production* (ed. C Smith), pp. 479–486. New York, NY: Academic Press.
21. Dahlberg C, Chao L. 2003 Amelioration of the cost of conjugative plasmid carriage in *Escherichia coli* K12. *Genetics* **165**, 1641–1649.
22. Day T, Huijben S, Read AF. 2015 Is selection relevant in the evolutionary emergence of drug resistance? *Trends Microbiol.* **23**, 126–133. (doi:10.1016/j.tim.2015.01.005)
23. Kim JK, Kwon JY, Kim SK, Han SH, Won YJ, Lee JH, Kim CH, Fukatsu T, Lee BL. 2014 Purine biosynthesis, biofilm formation, and persistence of an insect-microbe gut symbiosis. *Appl. Environ. Microbiol.* **80**, 4374–4382. (doi:10.1128/AEM.00739-14)
24. Stewart PS, Costerton JW. 2001 Antibiotic resistance of bacteria in biofilms. *Lancet* **358**, 135–138. (doi:10.1016/s0140-6736(01)05321-1)
25. Sutherland IW, Hughes KA, Skillman LC, Tait K. 2004 The interaction of phage and biofilms. *FEMS Microbiol. Lett.* **232**, 1–6. (doi:10.1016/s0378-1097(04)00041-2)
26. Donlan RM. 2009 Preventing biofilms of clinically relevant organisms using bacteriophage. *Trends Microbiol.* **17**, 66–72. (doi:10.1016/j.tim.2008.11.002)
27. Forti F *et al.* 2018 Design of a broad-range bacteriophage cocktail that reduces *Pseudomonas aeruginosa* biofilms and treats acute infections in two animal models. *Antimicrob. Agents Chemother.* **62**, e02573-17. (doi:10.1128/AAC.02573-17)
28. Atad I, Zvuloni A, Loya Y, Rosenberg E. 2012 Phage therapy of the white plague-like disease of *Favia fava* in the Red Sea. *Coral Reefs* **31**, 665–670. (doi:10.1007/s00338-012-0900-5)
29. Cairns J *et al.* 2018 Black Queen evolution and trophic interactions determine plasmid survival after the disruption of the conjugation network. *mSystems* **3**, e00104-18. (doi:10.1128/mSystems.00104-18)
30. Mikonranta L, Buckling A, Jalasvuori M, Raymond B. 2019 Data from: Targeting antibiotic resistant bacteria with phages reduces bacterial density in an insect host. Dryad Digital Repository. (doi:10.5061/dryad.sc54383)